Partner Headlines - SNY

  1. Celgene, Regeneron Get Some Favorable News

    Investors Business Daily

  2. Odd, This: Big Pharma On Losing End of Pricing Dispute

    YCharts

  3. Regeneron, Alexion Big-Cap Biotechs Sales Seen Rising

    Investors Business Daily

  4. $176,000 or $295,00 a Year: Bizarre World of Orphan Drugs

    YCharts

  5. Novo Plunges On FDA Action

    Investors Business Daily

  6. Celgene, Regeneron Get Some Favorable News

    Investors Business Daily

  7. Novo Nordisk Hit By Diabetes Drug Delay; Sanofi Rises

    Investors Business Daily

  8. FDA Decision on Diabetes Drug Hurts Novo Nordisk, Helps ...

    YCharts

  9. Stocks Narrow To Thin Red Line; Generac Backslides

    Investors Business Daily

  10. Novo Nordisk Stock Falls, Sanofi Rises On Drug Delay

    Investors Business Daily

  11. UPDATE: Regeneron Pharm Announces Receipt of HSR Notice ...

    Benzinga

  12. Futures Cut Back Early Advance; Novo Nordisk Tumbles On ...

    Investors Business Daily

  13. Sanofi Q4 Profit Down 72%

    Benzinga

  14. Is My Doctor On the Payroll of Some Drug Maker? Now ...

    YCharts

  15. Pay-to-Delay Opponent, FTC Chief Leibowitz, Quits: ...

    YCharts

  16. Novo Nordisk Earnings Beat Views; Competition Looms

    Investors Business Daily

  17. My 4 Favorites from Europe's Best Recommended Dividend ...

    GuruFocus

  18. Novo Nordisk Stock Hits High After Q4 Profit Beat

    Investors Business Daily

  19. Time to Hedge Euro Risk?

    Benzinga

  20. A Peek Into The Market Before The Trading Starts

    Benzinga

  21. Genzyme's LEMTRADA Application for MS Accepted for ...

    Benzinga

  22. Genzyme's LEMTRADA Application for MS Accepted for ...

    Benzinga

  23. 2 Attractively Valued Blue Chips

    Benzinga

  24. S&P Likes 2 ETFs For Europe's Rebound

    Benzinga

  25. Should Johnson & Johnson Unload Troubled McNeil Consumer ...

    YCharts

  26. FTC: Pay-to-Delay Pharma Deals Cover $8.3 Billion in Revenue

    YCharts

  27. Santarus Wins Drug Approval, Offers Bullish Guidance

    Investors Business Daily

  28. Three Stocks to Buy for Flu Season

    Benzinga

  29. FDA lowers Ambien dosage

    Investors Business Daily

  30. Measuring Social Network Buzz Over Pharma Stocks

    YCharts

  31. Ambien, Related Drugs Get Dosage Cut From FDA

    Investors Business Daily

  32. How Warren Buffett Made Money with Foreign Stocks

    GuruFocus

  33. Medtech Stocks Moving As Conference Makes Waves

    Investors Business Daily

  34. Medtech Stocks Moving As Conference Makes Waves

    Investors Business Daily

  35. 4 Health Care ETFs Your Broker Forgot to Mention

    Benzinga

  36. Biogen Stock Falls After ALS Candidate Fails

    Investors Business Daily

  37. The 3 Most-Recommended Healthcare Stocks

    GuruFocus

  38. 16 Really Cheap International Dividend Achievers

    GuruFocus

  39. Will Prem Watsa Lose Money on Research In Motion?

    GuruFocus

  40. The Bullish Case For French Stocks

    GuruFocus

  41. Cell Therapy Might Be Poised For A Comeback

    Investors Business Daily

  42. Foreign Drugmakers Holding Up, But Some Have Flaws

    Investors Business Daily

  43. Benzinga's Top Upgrades

    Benzinga

  44. Dodge & Cox Explain Why They Are Overweight in ...

    GuruFocus

  45. Benzinga's M&A Chatter for Wednesday December 12, 2012

    Benzinga

  46. Benzinga's M&A Chatter for Tuesday December 11, 2012

    Benzinga

  47. Sanofi Phase II Trial of JAK2 Inhibitor in Myelofibrosis ...

    Benzinga

  48. Warren Buffett's Best-Yielding Dividend Stocks

    GuruFocus

  49. The Other Healthcare Stocks of Warren Buffett

    GuruFocus

  50. How Big Pharma Might Get Its R&D Act Together

    YCharts

  51. Teva provides weak '13 outlook

    Investors Business Daily

  52. Teva's Stock Falls After 2013 Guidance Falls Short

    Investors Business Daily

  53. Accenture Life Sciences Study: Worst of Pharma's Patent ...

    YCharts

  54. Name an Industry That Can Jack Prices Up 13% in This Economy

    YCharts

  55. Medical Device Makers: Repeal the New Tax!

    FOXBusiness

  56. If Only People Would Take Their Meds – Pharma Sales ...

    YCharts

  57. Genzyme's Once-Daily, Oral AUBAGIO Approved in Australia

    Benzinga

  58. Generics Maker Teva Pharmaceutical to Make Smaller ...

    YCharts

  59. Celgene up after trading bust

    Investors Business Daily

  60. Post Downgrade, Say Oui to France?

    Benzinga

  61. Celgene, Sanofi, Stryker Up After Inside-Trade Busts

    Investors Business Daily

  62. Stocks Rise As Fiscal Cliff Talks Raise Hopes

    Investors Business Daily

  63. Stocks Down Modestly; Regeneron Jumps, But Hibbett Slides

    Investors Business Daily

  64. From Earlier: CHMP Recommends Granting of Marketing ...

    Benzinga

  65. Big Pharma Gains Another Foe on Pay-to-Delay Deals: 31 ...

    YCharts

  66. An Anti-Psychotic Drug With its Own Issues: ...

    YCharts

  67. More Trouble for Big Pharma Stocks: AMA Calls for an End ...

    YCharts

  68. Amgen Cholesterol-Fighter Shows Promise, Shares Rise

    Investors Business Daily

  69. China Drug Market to Boom – Diabetes Alone a $3.2 ...

    YCharts

  70. Sanofi, Regeneron Begin Enrollment in CV Outcomes Trial ...

    Benzinga

  71. Zalicus Prednisporin Licensee Sanofi Provides Update on ...

    Benzinga

  72. Making a Cheap Drug Expensive: Sanofi's Efforts in the ...

    YCharts

  73. Global Squeeze on Pharma Prices Just Won't Ease Up: ...

    YCharts

  74. Novo Nordisk Gets EU Nod for Long-Lasting Insulin Drug

    FOXBusiness

  75. Ah, Geez, the Aussies, Too? Plush Patent Rights of Big ...

    YCharts

  76. Biogen slides on drug delay

    Investors Business Daily

  77. FDA Advisory Committee Votes to Recommend Isis' KYNAMRO

    Benzinga

  78. Biogen Stock Slips After FDA Delays MS Drug Review

    Investors Business Daily

  79. Pharma Industry Agrees to Price Cuts With Irish ...

    YCharts

  80. Don't Call it Bribery  And Whatever it Was, Abbott ...

    YCharts

  81. AAC Technologies Cools Off, Sinopharm Stumbles Higher

    Investors Business Daily

  82. One Reason Novartis is Expected to Overtake Pfizer in ...

    YCharts

  83. Sanofi's New Cancer Drug Rebuffed by Sloan-Kettering ...

    YCharts

  84. Celgene Drug Abraxane OK'd For Lung Cancer; Shares Up

    Investors Business Daily

  85. Sanofi's Genzyme to Present New Data from AUBAGIO and ...

    Benzinga

  86. Pharma's Pay-to-Delay Deals Boost Healthcare Costs (and ...

    YCharts

  87. Benzinga's M&A Chatter for Thursday October 4, 2012

    Benzinga

  88. Sarepta Stock Jumps On Muscular Dystrophy Drug Trial

    Investors Business Daily

  89. Sanofi To Buy Genfar

    Benzinga

  90. Merck's $1 Billion-a-Year Gardasil Vaccine Garners ...

    YCharts

  91. The 20 Biggest Healthcare Dividend Payer

    GuruFocus

  92. Bad News For Pharma In World's Second-Biggest Market

    YCharts

  93. Not So Bad After All For Europe ETFs

    Benzinga

  94. What's Pharma R&D Really Producing? Another Take on the ...

    YCharts

  95. FDA Approves Genzyme's AUBAGIO Oral Treatment for ...

    Benzinga

  96. Confused by Pharma Stocks' Hefty Dividends, Weak Drug ...

    YCharts

  97. Pharma Trouble: Drug Approvals at FDA Could Slow or Halt ...

    YCharts

  98. Seven Cheap Large-Caps Yielding Over 4%

    Benzinga

  99. Three Biotech Stocks Analysts Are Keen On (MDVN, GEVA, OPTR)

    Benzinga

  100. Stocks Hold Mild Gains; Cheesecake Factory Tops Base

    Investors Business Daily
Marketplace
Trading Center